Rexahn Pharmaceuticals Completes Stage 1 and Begins Enrollment in Stage 2 of Archexin® Phase IIa Clinical Trial in Metastatic ...
ROCKVILLE, Md., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that it has identified a maximum …